Clinical Trial Update: Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

View source ↗

Summary

A clinical trial evaluating pembrolizumab with neoadjuvant chemo-immunotherapy for early-stage triple-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Emory University | Conditions: Breast Cancer Triple Negative, Breast Cancer Stage II | Status: RECRUITING